Abstract

Analytical method helps in ensuring the safety and efficacy of drugs in different matrices by determining the quantity and quality of Drug. A detailed extensive literature survey is one of the most essential requirements for all focused research activities. Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It is used to treat several diseases including major depressive disorder, obsessive-compulsive disorder, social anxiety disorder, panic disorder, posttraumatic stress disorder, generalized anxiety disorder, and premenstrual dysphoric disorder. Sincere effort has been made in the present review to collate all the relevant literature published in various pharmaceutical journals for determination of Paroxetine in different matrices both individually and in combination with other drugs. In this article main emphasis is given on the various techniques which are used for the estimation of the Paroxetine from various Pharmaceutical dosage forms or in biological matrices. The review highlights the basic as well as advanced techniques performed for estimating Paroxetine. Among different methods, HPLC and UV-Visible spectrophotometry are the most widely used techniques applied by the researchers. Detailed validation parameters are also given for the methods, which helps the researchers to select an analytical technique based on the information sought.

Keywords: Paroxetine; Analytical Methods; Estimation; Matrices; HPLC

References

1. Kessler RC., et al. “Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication”. Archives Of General Psychiatry 62 (2005): 593-602.
2. Shearer SL., et al. “Recent Advances in the Understanding and Treatment of Anxiety Disorders”. Primary Care Clinics in Office Practice 34 (2007): 475-504.
3. Mendlowicz MV., et al. “Quality of life in individuals with anxiety disorders”. American Journal of Psychiatry 157.5 (2000): 669-682.
4. Nemeroff CB., et al. “The Role of GABA in the Pathophysiology and Treatment of Anxiety Disorders”. Psychopharmacology Bulletin 37.4 (2003): 133-146.
5. Somers JM., et al. “Prevalence and incidence studies of anxiety disorders: a systematic review of the literature”. Canadian Journal of Psychiatry 51.2 (2006): 100‐113.
6. Ressler KJ., et al. “Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders”. Depression and Anxiety 12.1 (2000): 2-19.
7. Feldman S., et al. “Involvement of endogenous glutamate in the stimulatory effect of norepinephrine and serotonin on the hypothalamo-pituitary-adrenocortical axis”. Neuroendocrinology 79.1 (2004): 43-53.
8. Dubovsky SL., et al. “Beyond specificity: effects of serotonin and serotonergic treatments on psychobiological dysfunction”. Journal of Psychosomatic Research 39. (1995): 429-444.
9. Soodan S., et al. “Understanding the Pathophysiology and Management of the Anxiety Disorders”. International Journal of Pharmacy and Pharmaceutical Research 4.3 (2015): 251-278. 
10. Drug profile of Paroxetine” ? (2019).
11. Paxil - SSRI for the Treatment of Major Depressive Disorders. 
12. Paroxetine brands in india” (2019).
13. Medline India” (2019).
14. Sharma MC., et al. “Validated simultaneous spectrophotometric estimation of Paroxetine hcl bulk and tablet dosage form using ferric chloride”. Journal of Optoelectronics and Biomedical Material 2.4 (2010): 185-189.
15. Naik J., et al. “UV Spectrophotometric method development and validation for determination of Paroxetine hydrochloride in pharmaceutical dosage form”. International Journal of Pharmacy and Pharmaceutical Science 2.2 (2010): 43-45.
16. Panchumarthy R., et al. “Validated UV spectrophotometric method for quantitative analysis of Paroxetine in bulk and pharmaceutical dosage form”. Der Pharmacia Lettre 8.3 (2016): 254-260.
17. Praveen Kumar B., et al. “Development and validation of novel UV spectrophotometric and RP-HPLC method for the estimation of Paroxetine hydrochloride in bulk and pharmaceutical dosage forms”. Der Pharmacia Lettre 8.11 (2016): 1-9.
18. Reddy S., et al. “Method Development and Validation of Visible Spectroscopic Method for the Estimation of Paroxetine Hydrochloride in Pure and Tablet Dosage Form”. Chemical Science Transactions 6.4 (2018): 679-684.
19. Patel U., et al. “Application of Ratio Derivative Spectrophotometry for Simultaneous Determination of Clonazepam and Paroxetine Hydrochloride in Tablet Dosage Form”. Journal of Pharmaceutical Research and Reviews 2.8 (2018): 1-9.
20. Walash MI., et al. “Spectrophotometric Determination of the Antidepressants Sertraline and Paroxetine HCl using 2,4-Dinitrofluorobenzene”. International journal of Biomedical Science 6.3 (2010): 252-259.
21. Sheeja VK., et al. “Method Development and Validation for the Simultaneous Estimation of Clonazepam and Paroxetine in Combined Dosage form using Colorimetry” . Asian Journal of Research in Chemistry 7.1 (2014): 1-4.
22. Alarfaj N., et al. “Spectrofluorimetric Determination of Paroxetine Hydrochloride in Its Formulations and Human Plasma”. Chemical and Pharmaceutical Bulletin 54.4 (2006): 564-566.
23. Omar MA., et al. “Spectrofluorimetric determination of certain antidepressant drugs in human plasma Spectrofluorimetric protocol for antidepressant drugs in dosage forms and human plasma through derivatization with dansyl chloride”. Arabian Journal of Chemistry10.2 (2017): S3197-S3206.
24. Ruchita SD., et al. “Spectrofluorometric Analysis of New-Generation Antidepressant Drugs in Pharmaceutical Formulations, Human Urine, and Plasma Samples”. Spectroscopy: An International Journal 27.2 (2012): 59-71.
25. Darwish IA., et al. “New spectrofluorimetric method with enhanced sensitivity for determination of paroxetine in dosage forms and plasma”. Analytical Cheistry Insight 3 (2008): 145-155.
26. Patel J., et al. “A Synchronous Fluorescence Spectrofluorometric Method for the Simultaneous Determination of Clonazepam and Paroxetine Hydrochloride in Combined Pharmaceutical Dose Form”. The Turkish Journal of Pharmaceutical Sciences 14 (2017): 251-256.
27. Surekha L., et al. “A Validated RP-HPLC Method For The Estimation of Paroxetine Hydrochloride In Bulk and Tablet Dosage Form”. Journal of Pharmacy Research 5.3 (2012): 1768-1770. 
28. Agrawal N., et al. “Determination of Paroxetine in Pharmaceutical Preparations Using HPLC with Electrochemical Detection”. The Open Analytical Chemistry Journal 7.1 (2013): 1-5.
29. Małgorzata LK., et al. “New validated HPLC methodology for the determination of (−)-trans- Paroxetine and its enantiomer in pharmaceutical formulations with use of ovomucoid chiral stationary phase”. Analytical and Bioanalytical Chemistry 406.15 (2014): 3697-3702.
30. Aziz U., et al. “Development and validation of RP-HPLC-PDA method for the simultaneous estimation of clonazepam and Paroxetine hydrochloride in bulk and tablet dosage forms”. Journal of Pharmacy Research 8.9 (2014): 1212-1217.
31. Rao HK., et al. “Reverse Phase High Performance Liquid Chromatographic Method for the Analysis of Paroxetine in Pharmaceutical Dosage Forms”. Asian Journal of Research in Chemistry 7.4 (2014): 397-400.
32. Shrikanth A., et al. “RP-HPLC Method Development and Validation for Simultaneous Estimation of Clonazepam and Paroxetine in Tablet Dosage Forms”. European Journal of pharmaceutical and Medical Research 5.6 (2018): 330-336.
33. Reddy S., et al. “Development and Validation of a Stability Indicating Liquid Chromatographic Method for the Simultaneous Estimation of Paroxetine and Clonazepam in Bulk and its Pharmaceutical Formulations”. International Journal of Pharmacy and Pharmaceutical Sciences 6.10 (2014): 397-402. 
34. Yanamadala G., et al. “Development and Validation of a Stability-Indicating HPLC Method for the Simultaneous Determination of Paroxetine Hydrochloride and Clonazepam in Pharmaceutical Dosage Forms ”. International Journal of Pharmacy 4.1 (2014): 448-457.
35. Ibrahim F., et al. “Micellar HighPerformance Liquid Chromatographic Method for Simultaneous Determination of Clonazepam and Paroxetine HCl in Pharmaceutical Preparations Using Monolithic Column”. Journal of Chromatography Separation Techniques 7.4 (2014): 1-8.
36. Naidu N., et al. “Assay Method Development and Validation for Simultaneous Estimation of Paroxetine and Clonazepam by RP- HPLC”. World Journal of Pharmaceutical and Medical Journal 4.4 (2018): 232-236 .
37. Niki VA., et al. “Development and Validation of an HPLC Method, with Fluorescence Detection, for Simultaneous Determination of Paroxetine and its Metabolites in Plasma”. Journal of Liquid Chromatography and Related Technologies 30 (2007): 1641-1655.
38. Bhagyasree T., et al. “Assay Method Development and Validation for Simultaneous Estimation of Paroxetine And Clonazepam By RP- HPLC”. International Journal of Pharmaceutical Research and Analysis 4.8 (2014): 421-427.
39. Praveen Kumar B., et al. “Development and validation of novel UV spectrophotometric and RP-HPLC method for the estimation of Paroxetine hydrochloride in bulk and pharmaceutical dosage forms”. Der Pharmacia Lettre 8.11 (2016): 1-9.
40. Erk N., et al. “Voltammetric and HPLC techniques for the determination of paroxetine hydrochloride”. Die Pharmazie 58 (2014): 699-704.
41. Mireia Segura., et al. “Quantitative determination of paroxetine and its 4‐hydroxy‐3‐methoxy metabolite in plasma by high‐performance liquid chromatography/electrospray ion trap mass spectrometry: application to pharmacokinetic studies”. Rapid Communication in Mass Spectrometry 17.1315 (2003): 1455-1461.
42. Massaroti P., et al. “Validation of a Selective Method for Determination of Paroxetine in human plasma by LC-MS/MS”. Journal of Pharmacy and Pharmaceutical Sciences 8.2 (2005): 340-347.
43. Sulthana PS., et al. “Assay Method Development and Validation for Simultaneous Estimation of Paroxetine and Clonazepam by RP-HPLC”. European Journal of Biomedical and Pharmaceutical Sciences 4.7 (2017): 267-272.
44. Schatz D., et al. “Simultaneous Determination of Paroxetine, Risperidone and 9-Hydroxyrisperidone in Human Plasma by High-Performance Liquid Chromatography with Coulometric Detection”. Pharmacology 60 (2000): 51-56.
45. Umadurai M., et al. “Development and validation of a rapid UPLC Assay method for the simultaneous estimation of Paroxetine and clonazepam in tablet dosage form”. International Journal of Chemical and Pharmaceutical Sciences 5.4 (2014): 42-47.
46. Sharma RN., et al. “Validated TLC Densitometric Method for the Quantification of Paroxetine Hydrochloride in Solid Dosage”. Indian Journal of Pharmaceutical Sciences 69.3 (2007): 436-438.
47. Shah P., et al. “Development and Validation of HPTLC Method for Simultaneous Estimation of Clonazepam and Paroxetine Hydrochloride using DOE Approach”. Journal of Taibah University for Science 11.1 (2015): 121-132.

Citation

Citation: Satchitkrishna Radharapu., et al. “In Depth Investigation of Quantitative Analytical and Bioanalytical Techniques of Paroxetine in Different Matrices: A Review". Acta Scientific Pharmaceutical Sciences 4.7 (2020): 69-83.

Copyright

Copyright: © 2020 Satchitkrishna Radharapu., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.